Disease · MONDO_0005136
Comparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 43
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Enhanced Treatment vs Current Practice: serious adverse events | 6 of 1,017 | 15 of 2,108 | 3,125 | NCT00513500 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine) | 265 of 963 | 2,066 of 2,084 | 3,047 | NCT00513500 | Trial comparisons |
| Single MDA vs Repeated MDA: deaths from any cause | 5 of 1,265 | 15 of 1,447 | 2,712 | NCT02509481 | Trial comparisons |
| Single MDA vs Repeated MDA: serious adverse events | 10 of 1,265 | 19 of 1,447 | 2,712 | NCT02509481 | Trial comparisons |
| 1 Artemether-Lumefantrine vs 2 Amodiaquine-Artesunate: Cure Rate Day 14 | 192 of 204 | 563 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): deaths from any cause | 2 of 204 | 2 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantrine AL vs 2 Amodiaquine-Artesunate AQ-AS: Cure Rate on Day 28 | 197 of 204 | 603 of 612 | 816 | NCT00297882 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events | 6 of 204 | 3 of 612 | 816 | NCT00297882 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children Who do Not Respond to Treatment for Pneumonia | 41 of 362 | 41 of 203 | 565 | NCT00513500 | Trial comparisons |
| PA Group vs AL Group: deaths from any cause | 0 of 355 | 0 of 180 | 535 | NCT00541385 | Trial comparisons |
| PA Group vs AL Group: serious adverse events | 1 of 355 | 0 of 180 | 535 | NCT00541385 | Trial comparisons |
| Single MDA vs Repeated MDA: Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH) | 3 of 122 | 0 of 110 | 232 | NCT02509481 | Trial comparisons |
| Treatment vs Control: serious adverse events | 0 of 50 | 0 of 46 | 96 | NCT00473837 | Trial comparisons |
| AS + oAC vs AS Only (Water): Safety | 35 of 35 | 35 of 35 | 70 | NCT01955382 | Trial comparisons |
| AS + oAC vs AS Only (Water): serious adverse events | 0 of 35 | 0 of 35 | 70 | NCT01955382 | Trial comparisons |
| AQ-13 vs Coartem Treatment: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. | 28 of 33 | 31 of 33 | 66 | NCT01614964 | Trial comparisons |
| AQ-13 vs Coartem Treatment: deaths from any cause | 0 of 33 | 0 of 33 | 66 | NCT01614964 | Trial comparisons |
| AQ-13 vs Coartem Treatment: serious adverse events | 0 of 33 | 0 of 33 | 66 | NCT01614964 | Trial comparisons |
| AQ-13 vs Coartem Treatment: Number of Participants With Recrudescence of Infection | 0 of 28 | 2 of 33 | 61 | NCT01614964 | Trial comparisons |
| Cohort 1 vs Cohort 2: Number of Participants With Serious Adverse Events (SAEs) | 0 of 22 | 0 of 6 | 28 | NCT04300309 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005136/comparisons